184 related articles for article (PubMed ID: 8645359)
1. Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia.
Kajinami K; Nishitsuji M; Takeda Y; Shimizu M; Koizumi J; Mabuchi H
Atherosclerosis; 1996 Feb; 120(1-2):181-7. PubMed ID: 8645359
[TBL] [Abstract][Full Text] [Related]
2. Effects of probucol on xanthomata regression in familial hypercholesterolemia.
Yamamoto A; Matsuzawa Y; Yokoyama S; Funahashi T; Yamamura T; Kishino B
Am J Cardiol; 1986 Jun; 57(16):29H-35H. PubMed ID: 3728307
[TBL] [Abstract][Full Text] [Related]
3. Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study.
Mangili LC; Miname MH; Silva PRS; Bittencourt MS; Rocha VZ; Mangili OC; Salgado Filho W; Chacra AP; Jannes CE; Pereira AC; Santos RD
Atherosclerosis; 2017 Aug; 263():393-397. PubMed ID: 28499609
[TBL] [Abstract][Full Text] [Related]
4. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma.
Inazu A; Koizumi J; Kajinami K; Kiyohar T; Chichibu K; Mabuchi H
Atherosclerosis; 1999 Aug; 145(2):405-13. PubMed ID: 10488970
[TBL] [Abstract][Full Text] [Related]
5. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
Matsuzawa Y; Yamashita S; Funahashi T; Yamamoto A; Tarui S
Am J Cardiol; 1988 Jul; 62(3):66B-72B. PubMed ID: 3394656
[TBL] [Abstract][Full Text] [Related]
6. Severe xanthomatosis in heterozygous familial hypercholesterolemia.
Aljenedil S; Ruel I; Watters K; Genest J
J Clin Lipidol; 2018; 12(4):872-877. PubMed ID: 29778561
[TBL] [Abstract][Full Text] [Related]
7. Effects of probucol on homozygous cases of familial hypercholesterolemia.
Yamamoto A; Matsuzawa Y; Kishino B; Hayashi R; Hirobe K; Kikkawa T
Atherosclerosis; 1983 Aug; 48(2):157-66. PubMed ID: 6615580
[TBL] [Abstract][Full Text] [Related]
8. Non-macrophage-related accumulation of cholesterol during probucol treatment in familial hypercholesterolemia: report of two cases.
Nakamura T; Ueyama Y; Funahashi T; Yamashita S; Takemura KK; Kubo M; Yamada K; Matsuzawa Y
Atherosclerosis; 1992 Feb; 92(2-3):193-202. PubMed ID: 1632848
[TBL] [Abstract][Full Text] [Related]
9. [Influence of low high-density lipoprotein cholesterolemia induced by probucol on the progression of coronary atherosclerosis].
Takahashi T; Hiasa Y; Harada S; Hosokawa S; Kato S; Tanimoto M; Kishi K; Ohtani R
J Cardiol; 1997 Aug; 30(2):67-72. PubMed ID: 9300286
[TBL] [Abstract][Full Text] [Related]
10. [A case of heterozygous familial hypercholesterolemia showing the regression of coronary atherosclerosis by LDL-apheresis].
Nomura S; Kouzuma R; Komura T; Sadayasu T; Segawa J; Nakashima Y; Kuroiwa A
Kokyu To Junkan; 1992 Mar; 40(3):299-302. PubMed ID: 1579754
[TBL] [Abstract][Full Text] [Related]
11. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators.
Tatami R; Inoue N; Itoh H; Kishino B; Koga N; Nakashima Y; Nishide T; Okamura K; Saito Y; Teramoto T
Atherosclerosis; 1992 Jul; 95(1):1-13. PubMed ID: 1642687
[TBL] [Abstract][Full Text] [Related]
12. Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).
Yamashita S; Arai H; Bujo H; Masuda D; Ohama T; Ishibashi T; Yanagi K; Doi Y; Nakagawa S; Yamashiro K; Tanabe K; Kita T; Matsuzaki M; Saito Y; Fukushima M; Matsuzawa Y;
J Atheroscler Thromb; 2021 Feb; 28(2):103-123. PubMed ID: 32336695
[TBL] [Abstract][Full Text] [Related]
13. [Probucol treatment of hyperlipidemia].
Koizumi J
Nihon Rinsho; 1994 Dec; 52(12):3279-84. PubMed ID: 7853723
[TBL] [Abstract][Full Text] [Related]
14. Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery disease.
Kuo PT; Wilson AC; Kostis JB; Moreyra AE
Am J Cardiol; 1986 Jun; 57(16):43H-48H. PubMed ID: 3524177
[TBL] [Abstract][Full Text] [Related]
15. Long-term effect of low-density lipoprotein apheresis in a patient with heterozygous familial hypercholesterolemia: follow-up study using coronary angiography.
Saku K; Takeda Y; Jimi S; Okabe M; Shirai K; Nii T; Naito S; Arakawa K
J Cardiol; 1998 Apr; 31(4):239-45. PubMed ID: 9594373
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia.
Durrington PN; Miller JP
Atherosclerosis; 1985 May; 55(2):187-94. PubMed ID: 3890872
[TBL] [Abstract][Full Text] [Related]
17. New combined therapy of niceritrol and probucol on heterozygous familial hypercholesterolemia.
Yamamoto K; Fukushima N; Ozaki I; Setoguchi Y; Yanagita T; Sakai T
Artery; 1991; 18(3):133-49. PubMed ID: 2069518
[TBL] [Abstract][Full Text] [Related]
18. The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia.
Koga N
Ther Apher; 1997 Aug; 1(3):260-70. PubMed ID: 10225750
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia.
Mabuchi H; Koizumi J; Kajinami K
Am J Cardiol; 1998 Aug; 82(4B):52J-55J. PubMed ID: 9737647
[TBL] [Abstract][Full Text] [Related]
20. Coronary artery bypass grafting in familial hypercholesterolemia.
Kawasuji M; Sakakibara N; Takemura H; Matsumoto Y; Mabuchi H; Watanabe Y
J Thorac Cardiovasc Surg; 1995 Feb; 109(2):364-9. PubMed ID: 7853888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
